EA201791907A1 - Бивалентная вакцина против вируса свиного гриппа - Google Patents

Бивалентная вакцина против вируса свиного гриппа

Info

Publication number
EA201791907A1
EA201791907A1 EA201791907A EA201791907A EA201791907A1 EA 201791907 A1 EA201791907 A1 EA 201791907A1 EA 201791907 A EA201791907 A EA 201791907A EA 201791907 A EA201791907 A EA 201791907A EA 201791907 A1 EA201791907 A1 EA 201791907A1
Authority
EA
Eurasian Patent Office
Prior art keywords
flu virus
swine flu
subject
vaccine against
bivalent vaccine
Prior art date
Application number
EA201791907A
Other languages
English (en)
Inventor
Марк Аллан Айхмайер
Уэсли Скотт Джонсон
Эрик Мартин Вон
Мишель Л. Вальц
Original Assignee
Бёрингер Ингельхайм Ветмедика Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бёрингер Ингельхайм Ветмедика Гмбх filed Critical Бёрингер Ингельхайм Ветмедика Гмбх
Publication of EA201791907A1 publication Critical patent/EA201791907A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Изобретение относится к иммуногенной композиции, которая включает: a) модифицированный живой H3 вирус свиного гриппа и b) модифицированный живой H1 вирус свиного гриппа. Кроме того, данное изобретение относится к способам иммунизации субъекта, который включает введение такому субъекту иммуногенной композиции в соответствии с настоящим изобретением. Более того, настоящее изобретение относится к способам лечения или предотвращения клинических признаков, вызванных вирусом свиного гриппа у субъекта, который в этом нуждается, где способ включает введение субъекту терапевтически эффективного количества иммуногенной композиции в соответствии с настоящим изобретением.
EA201791907A 2015-02-26 2016-02-23 Бивалентная вакцина против вируса свиного гриппа EA201791907A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562121181P 2015-02-26 2015-02-26
PCT/US2016/019037 WO2016137929A1 (en) 2015-02-26 2016-02-23 Bivalent swine influenza virus vaccine

Publications (1)

Publication Number Publication Date
EA201791907A1 true EA201791907A1 (ru) 2018-02-28

Family

ID=55487152

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201791907A EA201791907A1 (ru) 2015-02-26 2016-02-23 Бивалентная вакцина против вируса свиного гриппа

Country Status (13)

Country Link
US (2) US10029005B2 (ru)
EP (1) EP3261664A1 (ru)
JP (1) JP6722686B2 (ru)
KR (1) KR20170122786A (ru)
CN (1) CN107250353B (ru)
AU (1) AU2016222962B2 (ru)
BR (1) BR112017015789A2 (ru)
CL (2) CL2017001961A1 (ru)
EA (1) EA201791907A1 (ru)
MX (1) MX2017010908A (ru)
PH (1) PH12017501370A1 (ru)
TW (1) TWI711462B (ru)
WO (1) WO2016137929A1 (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0511776B1 (pt) 2004-06-01 2016-11-29 Sinai School Medicine vírus atenuado de influenza de suínos geneticamente engenheirado, formulação imunogênica, formulação farmacêutica, uso da formulação imunogênica, uso do vírus atenuado de influenza de suínos geneticamente engenheirado, uso da formulação farmacêutica e método para produzir uma vacina, uma formulação imunogênica ou uma formulação farmacêutica
CN107250353B (zh) 2015-02-26 2021-07-23 勃林格殷格翰动物保健有限公司 二价猪流感病毒疫苗
EP3727444A1 (en) * 2017-12-18 2020-10-28 Intervet International B.V. Swine influenza a virus vaccine
EP3728647A1 (en) 2017-12-20 2020-10-28 Boehringer Ingelheim Vetmedica GmbH Detection of modified live swine influenza virus vaccines
KR20210062015A (ko) * 2018-09-20 2021-05-28 베링거잉겔하임베트메디카게엠베하 변형된 pedv 스파이크 단백질
BR112021005255A2 (pt) * 2018-09-21 2021-06-29 Board Of Regents Of The University Of Nebraska método de produção e uso de genes para vacina contra a influenza centralizada universal
MX2021004907A (es) * 2018-10-31 2021-06-15 Boehringer Ingelheim Vetmedica Gmbh Vacuna de ibv 4/91 con proteina espicular heterologa.
BR112021008390A2 (pt) * 2018-10-31 2021-09-28 Boehringer Ingelheim Vetmedica Gmbh Vacina de ibv h52 com proteína da espícula heteróloga
MX2019014943A (es) * 2018-12-12 2020-08-06 Cambridge Tech Llc Vacuna universal contra la gripe.
US11642407B2 (en) * 2020-02-28 2023-05-09 Massachusetts Institute Of Technology Identification of variable influenza residues and uses thereof
CN113186173B (zh) * 2021-04-15 2023-03-31 上海生物制品研究所有限责任公司 一种基于减毒流感病毒载体的新型冠状病毒肺炎疫苗

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US4071618A (en) 1974-09-03 1978-01-31 Research Foundation For Microbial Diseases Of Osaka University Process for preparing virus disease live vaccines
JPS57136528A (en) 1981-02-09 1982-08-23 Hayashibara Biochem Lab Inc Preparation of viral vaccine
JPS5939831A (ja) 1982-08-27 1984-03-05 Biseibutsu Kagaku Kenkyusho:Kk 豚用インフルエンザウイルス不活化ワクチン
US4693981A (en) 1983-12-20 1987-09-15 Advanced Genetics Research Institute Preparation of inactivated viral vaccines
US5106619A (en) 1983-12-20 1992-04-21 Diamond Scientific Co. Preparation of inactivated viral vaccines
JPS60202827A (ja) 1984-03-28 1985-10-14 Chibaken 弱毒痘そうワクチン株
US5840520A (en) 1989-08-28 1998-11-24 Aviron Recombinant negative strand RNA virus expression systems
US5786199A (en) 1989-08-28 1998-07-28 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
US5854037A (en) 1989-08-28 1998-12-29 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
US5166057A (en) 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
US5766601A (en) 1990-08-08 1998-06-16 University Of Massachusetts Medical Center Cross-reactive influenza a immunization
ATE161190T1 (de) 1991-10-07 1998-01-15 Biogen Inc Vorbeugungsmethode oder behandlung von, durch antigen-präsentierende zellen hervorgerufene, hautkrankheiten mittels inhibitoren der cd2/lfa-3 wechselwirkung
US6162432A (en) 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
CA2096159C (en) 1992-05-14 2004-07-20 Hermann Katinger Peptides that induce antibodies which neutralize genetically divergent hiv-1 isolates
US7344722B1 (en) 1993-06-29 2008-03-18 The Regents Of The University Of Michigan Cold-adapted influenza virus
DK0702085T4 (da) 1994-07-18 2010-04-06 Conzelmann Karl Klaus Prof Dr Rekombinant infektiøs ikke-segmenteret negativ-strenget RNA-virus
US6300090B1 (en) 1994-07-29 2001-10-09 The Rockefeller University Methods of use of viral vectors to deliver antigen to dendritic cells
US6146873A (en) 1994-11-10 2000-11-14 Baxter Aktiengesellschaft Production of orthomyxoviruses in monkey kidney cells using protein-free media
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
DE69510207T3 (de) 1995-08-09 2007-02-15 Schweiz. Serum- & Impfinstitut Bern Verfahren zur Herstellung von infektiösen minussträngigen RNA-Viren
US5840565A (en) 1995-08-22 1998-11-24 The Regents Of The University Of California Methods for enhancing the production of viral vaccines in PKR-deficient cell culture
AU727923B2 (en) 1995-09-27 2001-01-04 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Production of infectious respiratory syncytial virus from cloned nucleotide sequences
BR9710363A (pt) 1996-07-15 2000-01-11 Us Gov Health & Human Serv "vìrus sincicial respirátorio recombinante infeccioso isolado, partìcula do mesmo, processos para estimular o sistema imunológico de um indivìduo para induzir proteção contra o vìrus sincicial respiratório e para produzir uma partìcula de vìrus sincicial respiratório recombinante, vacina para induzir proteção contra o vìrus sincicial respiratório recombinante composição e ceta de vìrus sincicial respiratório recombinante"
EP0932684A2 (en) 1996-09-27 1999-08-04 American Cyanamid Company 3' genomic promoter region and polymerase gene mutations responsible for attenuation in viruses of the order designated mononegavirales
IL131730A (en) 1997-03-05 2004-06-20 Univ Washington Screening methods to identify factors that selectively inhibit hepatitis C virus replication
US5891705A (en) 1997-04-08 1999-04-06 Pentose Pharmaceuticals, Inc. Method for inactivating a virus
US6884414B1 (en) 1997-04-30 2005-04-26 Mount Sinai School Of Medicine Of New York University Recombinant influenza viruses expressing tumor-associated antigens as antitumor agents
AU7797798A (en) 1997-05-23 1998-12-11 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Production of attenuated parainfluenza virus vaccines from cloned nucleotide sequences
EP1012244B1 (en) 1997-07-11 2007-05-09 Yale University Rhabdoviruses with reengineered coats
EP1015594A1 (en) 1997-09-19 2000-07-05 American Cyanamid Company Attenuated respiratory syncytial viruses
IL140265A0 (en) 1998-06-12 2002-02-10 Sinai School Medicine Methods and interferon deficient substrates for propagation of viruses
DK1098961T3 (da) 1998-06-12 2008-05-26 Andrej Y Dr Egorov Gensplejsede svækkede vira, der inducerer interferon
US6146642A (en) 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
US6544785B1 (en) 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
AT407958B (de) 1999-02-11 2001-07-25 Immuno Ag Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
ATE353370T1 (de) 1999-07-14 2007-02-15 Sinai School Medicine In vitro-rekonstitution von segmentierten, negativstrang-rna-viren
EP1259629B1 (en) 2000-03-02 2005-07-20 Polymun Scientific Immunbiologische Forschung GmbH Recombinant influenza a viruses
US6635416B2 (en) 2000-04-10 2003-10-21 Mount Sinai School Of Medicine Of New York University Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents
DE10020505A1 (de) 2000-04-26 2001-10-31 Conzelmann Karl Klaus RSV NS Proteine antagonisieren die Interferon (IFN) Antwort
ES2327103T3 (es) 2000-09-25 2009-10-26 Polymun Scientific Immunbiologische Forschung Gmbh Vacuna viva de influenzavirus y procedimiento de fabricacion.
AU2003290842A1 (en) 2002-11-13 2004-06-03 Rutgers, The State University Process for designing inhibitors of influenza virus non-structural protein 1
BRPI0511776B1 (pt) 2004-06-01 2016-11-29 Sinai School Medicine vírus atenuado de influenza de suínos geneticamente engenheirado, formulação imunogênica, formulação farmacêutica, uso da formulação imunogênica, uso do vírus atenuado de influenza de suínos geneticamente engenheirado, uso da formulação farmacêutica e método para produzir uma vacina, uma formulação imunogênica ou uma formulação farmacêutica
EP1855713B1 (en) 2005-02-15 2016-04-27 Mount Sinai School of Medicine Genetically engineered equine influenza virus and uses thereof
US20070116717A1 (en) 2005-08-01 2007-05-24 Shneider Alexander M Influenza vaccine compositions and methods
AT502275B8 (de) 2005-08-08 2007-08-15 Greenhills Biotechnology Res D Immunantwort-induzierende zusammensetzungen
TWI531652B (zh) 2005-12-02 2016-05-01 美國紐約大學西奈山醫學院 表現非原生表面蛋白質之嵌合病毒及其用途
US7507411B2 (en) 2006-06-23 2009-03-24 University Of Saskatchewan Attenuated influenza NS1 variants
WO2011014504A1 (en) 2009-07-27 2011-02-03 Mount Sinai School Of Medicine Of New York University Recombinant influenza virus vectors and uses thereof
CN102166352B (zh) * 2011-04-13 2013-01-23 华威特（北京）生物科技有限公司 猪流感二价灭活疫苗的制备方法及其产品
US20130189303A1 (en) 2011-08-02 2013-07-25 Yan Zhou Recombinant swine influenza virus and uses thereof
SG11201401137TA (en) * 2011-10-07 2014-07-30 Medimmune Llc Influenza hemagglutinin variants
CN103468647B (zh) * 2013-09-03 2015-04-22 华中农业大学 猪流感h1n1和h3n2亚型的二价灭活疫苗
CN107250353B (zh) 2015-02-26 2021-07-23 勃林格殷格翰动物保健有限公司 二价猪流感病毒疫苗

Also Published As

Publication number Publication date
US10905756B2 (en) 2021-02-02
JP2018512388A (ja) 2018-05-17
TWI711462B (zh) 2020-12-01
EP3261664A1 (en) 2018-01-03
US10029005B2 (en) 2018-07-24
US20160250318A1 (en) 2016-09-01
CL2018002692A1 (es) 2019-01-18
US20180289795A1 (en) 2018-10-11
TW201701900A (zh) 2017-01-16
AU2016222962A1 (en) 2017-07-13
PH12017501370A1 (en) 2017-12-18
JP6722686B2 (ja) 2020-07-15
MX2017010908A (es) 2017-12-07
KR20170122786A (ko) 2017-11-06
CN107250353A (zh) 2017-10-13
AU2016222962B2 (en) 2020-05-21
WO2016137929A1 (en) 2016-09-01
CN107250353B (zh) 2021-07-23
CL2017001961A1 (es) 2018-04-20
BR112017015789A2 (pt) 2018-03-27

Similar Documents

Publication Publication Date Title
EA201791907A1 (ru) Бивалентная вакцина против вируса свиного гриппа
EA201890735A1 (ru) Модуляторы корового белка вируса гепатита b
MX2021007679A (es) Anticuerpos humanos para hemaglutinina de influenza.
BR112018013387A2 (pt) vetor de vacinação recombinante, vírus mva, vacina ou composição farmacêutica e kit
EA201890999A1 (ru) Вакцина против вируса простого герпеса
EA201891000A1 (ru) Вакцина против респираторно-синцитиального вируса
EA201891186A1 (ru) Антитела, нейтрализующие вирус иммунодефицита человека
EA201792354A1 (ru) Композиции обетихолевой кислоты и способы применения
EA201691726A1 (ru) Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
EA201691261A1 (ru) Новые дигидрохинолизиноны для лечения и профилактики инфекции, вызванной вирусом гепатита b
BR112016001192A2 (pt) Vacina contra a raiva
EA201790294A1 (ru) Средства на основе флагеллина и применения, включающие эффективную вакцинацию
EA201990071A1 (ru) Композиция пептидной вакцины
EA201990010A1 (ru) Вакцина против вируса инфекционного бронхита
CL2019003805A1 (es) Composiciones inmunógenas de senecavirus a y métodos de éstas.
EA201800148A1 (ru) Оспенная вакцина для лечения рака
EA201890747A1 (ru) Способы лечения воспалительных заболеваний
EA201790787A1 (ru) Снижение вязкости фармацевтических составов
EA201890815A1 (ru) Аминокислотные композиции с модифицированным высвобождением для перорального введения
EA201991041A1 (ru) Вакцина против свиного парвовируса и вируса свиного репродуктивного и респираторного синдрома и способы ее получения
NZ731659A (en) Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
CO2017001087A2 (es) Anticuerpos anti proteína similar a angiopoyetina 4
EA201792512A1 (ru) Составы для доставки антигенов респираторного синтициального вируса и норовируса в тонкий кишечник
EA202191145A1 (ru) Вакцина виб 4/91 с гетерологичным шиповидным белком
EA201892003A1 (ru) Лечение атопического дерматита собак